Back

dr. R.M.T. (Renske) ten Ham

dr. R.M.T. (Renske) ten Ham

Assistant Professor
dr. R.M.T. (Renske) ten Ham
  • Department of Public Health, Healthcare Innovation & Evaluation and Medical Humanities (PHM)

Biography

Biography

Renske ten Ham is an assistant professor at the UMC Utrecht in the Netherlands and specializes in health economics & health technology assessment (HTA) of gene and cell-based products. Trained as a pharmacist and with an MSc in HTA, she holds a PhD in Drug Innovation titled: “Development, market authorization and market access of gene- and cell-based therapies”.

Over the years Renske conducted research at the University of California, San Francisco (UCSF), spend time at the Dutch Medicines Evaluation Board (CBG-MEB) and National Healthcare Institute (Zorginstituut Nederland).

Renske strives to facilitate translation of gene and cell-based therapies to increase patient access. She believes insights from (past) challenges will not only benefit gene and call-based therapies now, but also benefit development and translation of future biomedical innovations.

Side Activities

Current:

  • Co-chair - member engagement ISPOR Special Interest Group Precision Medicine and Advanced Therapies
  • Member - The Professional Society for Health Economics and Outcomes Research (ISPOR) 
  • Member - Dutch Association of Medical Technology Assessment (NVTAG)
  • Member - Dutch Association for Health Economics (VGE)

Fellowship and Awards

Publication featured as Trends Editors Pick 2020

Journal: Trends in Pharmacological Sciences

Awarded publication: Development and Regulation of Gene and Cell-Based Therapies in Europe: A Quantification and Reflection.

 

Publication featured as  Editors Pick 2020

Journal: Value in Health

Awarded publication: A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature.

 

Best Scientific Poster 2019

Conference: TOPRA Conference 2019

Awarded poster: Challenges in Advanced Therapy Medicinal Product Development

Research Output (4)

Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients

ten Ham Renske M.T., van Nuland Merel, Vreman Rick A., de Graaf Laurens G., Rosing Hilde, Bergman André M., Huitema Alwin D.R., Beijnen Jos H., Hövels Anke M. jan 2021, In: Value in Health. 24 , p. 121-128 8 p.

A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature

ten Ham RMT, Klungel Olaf, Leufkens H.G.M., Frederix GWJ sep 2020, In: Value in Health. 23 , p. 1268-1280 13 p.

What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings

Ham RMT, Hovels Anke M., Hoekman J., Frederix GW, Leufkens H.G.M., Klungel Olaf, Jedema I., Nikolic T., van Pel M., Zwaginga J.J., de Goede A., Schreibelt Gerty, de Vries I Jolanda M, Dolstra Harry, Ovelgonne H, Meij P, Mountford J.C., Turner M.L, Hoefnagel MHN jul 2020, In: Cytotherapy. 22 , p. 388-397 10 p.

Development and Regulation of Gene and Cell-Based Therapies in Europe: A Quantification and Reflection

ten Ham RM, Hovels Anke, Klungel Olaf, Broekmans André, Hoekman Jarno feb 2020, In: Trends in Pharmacological Sciences. 41 , p. 67-71 5 p.

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet